Wolfe Research initiated coverage of Arcellx (ACLX) with a Peer Perform rating and no price target The firm’s analyst of the FDA’s FAERS data suggests Carvytki’s neurotoxicity is decreasing, but the analyst says its “early to draw any conclusions.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx Inc.: Promising Developments and Strategic Positioning Drive Buy Rating
- Arcellx, Inc. Reports Increased Loss Amid Rising Expenses
- Arcellx’s Promising Clinical Data and Strong Financial Position Justify Buy Rating with $105 Target Price
- Promising Developments and Strategic Plans Boost Confidence in Arcellx Inc.’s Anito-cel
- Arcellx Inc’s Promising Developments and Strategic Partnerships Drive Buy Rating